| Literature DB >> 34250259 |
Lisa J Toelle1, Gabrielle E Hatton1, Jerrie S Refuerzo1, Charles E Wade1, Bryan A Cotton1, Lillian S Kao1.
Abstract
Circulating hormones affect coagulopathy in pregnancy and after trauma. The hemostatic profile of pregnant women after injury has not been characterized. We hypothesized that injured pregnant females would present with an initial thrombelastography (TEG) reflecting a more hypercoagulable profile and a higher incidence of venous thromboembolic events (VTE) when compared with non-pregnant females and males.Entities:
Keywords: blood coagulation; pregnancy; thrombelastography; venous thromboembolism
Year: 2021 PMID: 34250259 PMCID: PMC8230999 DOI: 10.1136/tsaco-2021-000714
Source DB: PubMed Journal: Trauma Surg Acute Care Open ISSN: 2397-5776
Rapid TEG interpretation
| r-TEG value | Definition | Interpretation |
| ACT (s) | Time from start of assay to initiation of clot | Prolonged with factor deficiency or severe hemodilution |
| Reaction time (min) | Time between beginning of assay and initial clot formation | Prolonged with factor deficiency or severe hemodilution |
| Kinetic time (min) | Time needed to reach 20 mm clot strength | Increased with hypofibrinogenemia or platelet dysfunction |
| α angle (°) | Rate or acceleration of clot formation | Decreased with hypofibrinogenemia or platelet dysfunction |
| Maximum amplitude (mm) | Contribution of platelet function and platelet–fibrin interactions | Decreased with platelet dysfunction and hypofibrinogenemia |
| LY-30 (%) | Amplitude reduction 30 min after achieving MA (degree of fibrinolysis) | Increased with accelerated fibrinolysis |
ACT, activated clotting time; LY-30, lysis 30 min after MA; MA, maximum amplitude; r-TEG, rapid TEG; TEG, thrombelastography.
Figure 1Thromboelastogram. Illustration of thrombelastography (TEG) tracing and the parameters measured through clot formation and fibrinolysis. The R-value expresses the time between the start of the assay and beginning of clot formation. The k-time is the time needed to reach 20 mm clot strength. The α angle is the slope of the tracing that represents rate of clot formation. The maximum amplitude (MA) is the greatest amplitude of the tracing and represents the strength of the fibrin clot. LY-30 is the percent amplitude reduction at 30 minutes after MA.
Characteristics of study participants
| Demographic | All patients | Pregnant | Non-pregnant | Male | P value* |
| Age (years) | 24 (20–30) | 24 (20–30) | 25 (20–31) | 24 (20–30) | 0.62 |
| Injury Severity Score | 10 (5–21) | 12 (5–21) | 12 (6–21) | 10 (5–21) | 0.83 |
| Head AIS | 0 (0–2) | 0 (0–3) | 0 (0–2) | 0 (0–2) | 0.79 |
| Face AIS | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0.77 |
| Chest AIS | 0 (0–3) | 0 (0–3) | 0 (0–3) | 0 (0–3) | 0.66 |
| Abdomen AIS | 0 (0–2) | 0 (0–2) | 0 (0–2) | 0 (0–2) | 0.48 |
| Extremity AIS | 1 (0–1) | 1 (0–1) | 1 (0–1) | 1 (0–1) | 0.58 |
| External AIS | 0 (0–3) | 2 (0–2) | 1 (0–3) | 0 (0–3) | 0.45 |
| Blunt mechanism | 409 (60%) | 67 (88%) | 192 (64%) | 150 (50%) | <0.001 |
| Transferred | 156 (23%) | 18 (24%) | 63 (20%) | 75 (25%) | 0.50 |
| Prehospital transfusion | 67 (10%) | 8 (11%) | 29 (10%) | 30 (10%) | 0.82 |
| ED SBP (mm Hg) | 122 (110–138) | 118 (104–133) | 119 (104–132) | 130 (114–142) | <0.001 |
| ED HR (bpm) | 100 (84–118) | 104 (86–118) | 104 (88–120) | 95 (81–115) | 0.002 |
| ED GCS | 15 (14–15) | 15 (14–15) | 15 (14–15) | 15 (14–15) | 0.54 |
| Hemoglobin (g/dL) | 13 (11.7–14.3) | 11.7 (10.6–12.2) | 12.4 (11.2–13.4) | 14.1 (13.2–15.0) | <0.001 |
| Platelets (×109/L) | 248 (206–297) | 230 (191–267) | 263 (216–317) | 243 (199–287) | <0.001 |
| Base excess | −2 (−5 to 0) | −3 (−5 to −2) | −3 (−6 to −1) | −2 (−4 to 0) | <0.001 |
Continuous data presented as median (IQR).
*Results of Kruskal-Wallis test.
AIS, Abbreviated Injury Scale; ED, emergency department; GCS, Glasgow Coma Scale; HR, heart rate; SBP, systolic blood pressure.
Rapid TEG results on arrival
| TEG parameter | All patients | Pregnant | Non-pregnant | Male | P value* |
| ACT (s) | 113 (105–121) | 113 (105–121) | 105 (105–113) | 113 (105–121) | <0.001 |
| Split point time (min) | 0.5 (0.4–0.6) | 0.5 (0.4–0.6) | 0.5 (0.4–0.6) | 0.6 (0.5–0.6) | 0.003 |
| Reaction time (min) | 0.7 (0.6–0.8) | 0.7 (0.6–0.8) | 0.6 (0.5–0.7) | 0.7 (0.6–0.8) | <0.001 |
| Kinetic time (min) | 1.2 (1.0–1.7) | 1.1 (0.9–1.2) | 1.2 (0.9–1.4) | 1.5 (1.2–1.8) | <0.001 |
| α angle (°) | 75 (71–77) | 77 (74–79) | 76 (73–78) | 72 (68–75) | <0.001 |
| Maximum amplitude (mm) | 65 (60–69) | 69 (65–72) | 67 (62–70) | 63 (57–66) | <0.001 |
| G-value (d/sc) | 9.1 (7.4–11.1) | 11 (9.3–13) | 9.9 (8.0–11.7) | 8.1 (6.7–9.5) | 0.001 |
| LY-30 (%) | 1.5 (0.4–3.2) | 0.8 (0–2.7) | 1.7 (0.5–3.4) | 1.5 (0.4–3.2) | 0.02 |
| Coagulation index | 3.7 (3.0–4.4) | 4.4 (3.8–4.8) | 4.1 (3.3–4.6) | 3.4 (2.7–3.9) | <0.001 |
| Hypocoagulable (MA ≤55) | 61 (9%) | 5 (7%) | 21 (7%) | 35 (12%) | 0.10 |
| Hypocoagulable (α angle ≤60°) | 24 (4%) | 3 (4%) | 6 (2%) | 15 (5%) | 0.14 |
| High LY-30 (lysis ≥3.0%) | 213 (31%) | 17 (22%) | 103 (34%) | 93 (31%) | 0.10 |
| Normocoagulable (MA 56–64) | 275 (41%) | 11 (14%) | 102 (34%) | 162 (54%) | <0.001 |
| Normocoagulable (α angle 61°–75°) | 379 (56%) | 24 (32%) | 137 (46%) | 218 (72%) | <0.001 |
| Physiologic lysis | 222 (33%) | 19 (25%) | 101 (34%) | 102 (34%) | 0.20 |
| Hypercoagulable (α angle ≥76°) | 275 (41%) | 49 (64%) | 158 (52%) | 68 (23%) | <0.001 |
| Hypercoagulable (MA ≥65) | 342 (50%) | 60 (79%) | 178 (59%) | 104 (34%) | <0.001 |
| Low LY-30 (lysis ≤0.8%) | 243 (36%) | 40 (53%) | 97 (32%) | 106 (35%) | 0.005 |
Continuous data presented as median (IQR).
*Results of Kruskal-Wallis test.
ACT, activated clotting time; LY-30, lysis 30 min after MA; MA, maximum amplitude; TEG, thrombelastography.
Outcomes of study participants
| Outcome | All patients | Pregnant | Non-pregnant | Male | P value* |
| Transfusion ≥1 u in 24 h | 114 (17%) | 12 (16%) | 52 (17%) | 50 (17%) | 0.95 |
| Tranexamic acid | 13 (2%) | 0 | 6 (2%) | 7 (2%) | 0.41 |
| Deep vein thrombosis | 6 (1%) | 0 | 3 (1%) | 3 (1%) | 0.68 |
| Pulmonary embolism | 8 (1%) | 0 | 7 (2%) | 1 (0.3%) | 0.05 |
| Length of stay (days) | 5 (2–11) | 4 (2–8) | 5 (2–12) | 4 (2–12) | 0.19 |
| Intensive care unit days | 0 (0–2) | 0 (0–1) | 0 (0–2) | 0 (0–2) | 0.21 |
| Ventilator days | 0 (0–1) | 0 (0–0) | 0 (0–1) | 0 (0–1) | 0.43 |
| Mortality | 29 (4%) | 4 (5%) | 16 (5%) | 9 (3%) | 0.33 |
Continuous data presented as median (IQR).
*Results of Kruskal-Wallis test.
Pregnancy demographics and obstetric outcomes
| Pregnancy demographics and obstetric outcomes | All patients | <23 weeks’ EGA | ≥23 weeks’ EGA | P value* |
| Estimated gestational age at arrival (weeks) | 22 (14–31) | 15 (8–19) | 31 (26–34) | <0.001 |
| Twin gestation | 1 (1%) | 1 (3%) | 0 | 0.34 |
| Peri-injury delivery | 27 (36%) | 11 (27%) | 16 (44%) | 0.12 |
| Emergent cesarean section | 7 (9%) | 0 | 7 (19%) | 0.003 |
| Preterm delivery (<38 weeks) | 24 (32%) | 10 (25%) | 18 (39%) | 0.19 |
| Fetal demise | 12 (16%) | 9 (23%) | 3 (8%) | 0.09 |
| Maternal death | 4 (5%) | 1 (3%) | 3 (8%) | 0.26 |
Continuous data presented as median (IQR).
*Results of Wilcoxon rank-sum test.
EGA, estimated gestational age.
Obstetric complications and TEG category
| Pregnancy demographics and obstetric outcomes | No pregnancy complication | Pregnancy complication (n=28) | P value |
| Hypocoagulable (MA ≤55) | 1 (2%) | 3 (11%) | 0.10 |
| Hypocoagulable (α angle ≤60°) | 0 | 3 (11%) | 0.02 |
| High LY-30 (lysis ≥3.0%) | 11 (23%) | 6 (21%) | 0.88 |
| Normocoagulable (MA 56–64) | 22 (46%) | 15 (54%) | 0.51 |
| Normocoagulable (α angle 61°–75°) | 13 (27%) | 11 (39%) | 0.27 |
| Physiologic LY-30 | 13 (27%) | 6 (21%) | 0.58 |
| Hypercoagulable (α angle ≥76°) | 35 (73%) | 14 (50%) | 0.04 |
| Hypercoagulable (MA ≥65) | 25 (36% | 10 (52%) | 0.16 |
| Low LY-30 (lysis ≤0.8%) | 24 (50%) | 16 (57%) | 0.54 |
LY-30, lysis 30 min after MA; MA, maximum amplitude; TEG, thrombelastography.